
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6238027/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Risk of Hepatitis B Virus (HBV) Reactivation in Patients with Immune-Mediated Inflammatory Diseases Receiving Biologics: Focus on the Timing of Biologics after Anti-HBV Treatment. Gut and Liver, 2022, 16, 567-574.	1.4	2
2	Initial Preserved Renal Function as a Predictor of Favorable Renal Response to Rituximab in Refractory or Relapsing Lupus Nephritis: A Single-center Cohort Study in Korea. Journal of Rheumatic Diseases, 2022, 29, 22-32.	0.4	5
3	Risk of Acute Anterior Uveitis in Ankylosing Spondylitis According to the Type of Tumor Necrosis Factor-Alpha Inhibitor and History of Uveitis: A Nationwide Population-Based Study. Journal of Clinical Medicine, 2022, 11, 631.	1.0	3
4	The Value of Thermal Imaging for Knee Arthritis: A Single-Center Observational Study. Yonsei Medical Journal, 2022, 63, 141.	0.9	6
5	Safety of JAK inhibitor use in patients with rheumatoid arthritis who developed herpes zoster after receiving JAK inhibitors. Clinical Rheumatology, 2022, 41, 1659-1663.	1.0	5
6	Comparison of the Seven Interleukin-32 Isoforms' Biological Activities: IL-32Î, Possesses the Most Dominant Biological Activity. Frontiers in Immunology, 2022, 13, 837588.	2.2	5
7	Treatment pattern, satisfaction, and productivity loss of patients with ankylosing spondylitis treated with tumor necrosis factor inhibitors in Korea: A multicenter crossâ€sectional observational study. International Journal of Rheumatic Diseases, 2022, 25, 523-531.	0.9	11
8	A Paradoxical Effect of Interleukin-32 Isoforms on Cancer. Frontiers in Immunology, 2022, 13, 837590.	2.2	7
9	Idiopathic Inflammatory Arthritis in the Auditory Canal in a Patient With Hearing Impairment: A Case Report and Literature Review. Journal of Rheumatic Diseases, 2022, 29, 116-122.	0.4	0
10	Renal outcomes of transient proteinuria in patients with systemic lupus erythematosus treated with corticosteroid therapy alone. Lupus, 2022, , 096120332210935.	0.8	1
11	Risk of New-Onset Diabetes Mellitus Associated with Antirheumatic Drugs in Patients with Rheumatoid Arthritis: A Nationwide Population Study. Journal of Clinical Medicine, 2022, 11, 2109.	1.0	5
12	Predictive Factors for Rheumatoid Arthritis Flare After Switching From Intravenous to Subcutaneous Formulation of Tocilizumab in Real-World Practice. Journal of Korean Medical Science, 2022, 37, e138.	1.1	3
13	Macrophage activation syndrome in rheumatic disease: Clinical characteristics and prognosis of 20 adult patients. PLoS ONE, 2022, 17, e0267715.	1.1	6
14	Expression of Inflammatory Markers in the Muscles of Patients with Idiopathic Inflammatory Myopathy According to the Presence of Interstitial Lung Disease. Journal of Clinical Medicine, 2022, 11, 3021.	1.0	1
15	Anti-tumor necrosis factor-induced lupus in patients with inflammatory bowel disease: a hospital-based cohort study from Korea. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482199779.	1.4	3
16	Case of a 21-Year-Old Man With Hemoptysis, Recurrent Pneumothorax, and Cavitary Lung Lesions. Chest, 2021, 159, e13-e17.	0.4	0
17	Biologic therapies for the treatment of ankylosing spondylitis. Journal of the Korean Medical Association, 2021, 64, 116-123.	0.1	1
18	Recent Hydroxychloroquine Use Is Not Significantly Associated with Positive PCR Results for SARS-CoV-2: A Nationwide Observational Study in South Korea. Viruses, 2021, 13, 329.	1.5	4

#	Article	IF	CITATIONS
19	Neutrophil extracellular trap clearance by synovial macrophages in gout. Arthritis Research and Therapy, 2021, 23, 88.	1.6	15
20	Risk of progression of idiopathic pulmonary fibrosis to connective tissue disease: a long-term observational study in 527 patients. Clinical Rheumatology, 2021, 40, 2447-2456.	1.0	4
21	Pregnancy outcomes in Korean women with ankylosing spondylitis. Korean Journal of Internal Medicine, 2021, 36, 721-730.	0.7	16
22	Blocking TNFα attenuates progressive cartilage matrix degradation in inflammatory arthritis. Experimental and Therapeutic Medicine, 2021, 22, 808.	0.8	6
23	Urine β-2-glycoprotein 1 as a biomarker for diagnosis of systemic lupus erythematosus. Lupus, 2021, 30, 1306-1313.	0.8	2
24	Comparative efficacy of low-dose versus regular-dose colchicine to prevent flares in gout patients initiated on urate-lowering therapies. Rheumatology, 2021, 61, 223-229.	0.9	7
25	Machine learning model for identifying important clinical features for predicting remission in patients with rheumatoid arthritis treated with biologics. Arthritis Research and Therapy, 2021, 23, 178.	1.6	20
26	Clinical characteristics of nonâ€radiographic axial spondyloarthritis: Results of the Korean Nonradiographic Axial SPondyloArthritis (KONASPA) data. International Journal of Rheumatic Diseases, 2021, 24, 1137-1147.	0.9	4
27	Acetylated Diacylglycerol 1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol in Autoimmune Arthritis and Interstitial Lung Disease in SKG Mice. Biomedicines, 2021, 9, 1095.	1.4	2
28	Angiographic patterns and temporal changes of arterial lesions in Behcet's disease. Vascular, 2021, , 170853812110464.	0.4	0
29	Treatment Response to Idiopathic Retroperitoneal Fibrosis-associated Hydronephrosis With a Focus on IgG4/IgG3 Serum Concentration Ratio. Journal of Rheumatic Diseases, 2021, 28, 38-44.	0.4	1
30	Risk of Cancer in Middle-aged Patients With Gout: A Nationwide Population-based Study in Korea. Journal of Rheumatology, 2021, 48, 1465-1471.	1.0	9
31	Anaphylaxis to tocilizumab in patients with rheumatic disease. Immunotherapy, 2021, 13, 1483-1489.	1.0	1
32	Progressive fibrosing interstitial lung disease: prevalence and clinical outcome. Respiratory Research, 2021, 22, 282.	1.4	28
33	Discovery of urine biomarkers for lupus nephritis via quantitative and comparative proteome analysis. Clinical and Translational Medicine, 2021, 11, e638.	1.7	4
34	SARS-CoV-2 Omicron Mutation Is Faster than the Chase: Multiple Mutations on Spike/ACE2 Interaction Residues. Immune Network, 2021, 21, e38.	1.6	42
35	Reasons for the High Cesarean Delivery Rate among Women with Ankylosing Spondylitis: Using the Korean National Health Insurance Database. Journal of Rheumatology, 2020, 47, 668-673.	1.0	4
36	Effect of TNF inhibitors on bone mineral density in rheumatoid arthritis patients receiving bisphosphonate: a retrospective cohort study. Rheumatology International, 2020, 40, 481-487.	1.5	9

#	Article	IF	CITATIONS
37	Discontinuing febuxostat might cause more deaths than continuing febuxostat: the untold story from the CARES trial. Rheumatology, 2020, 59, 1439-1440.	0.9	10
38	Recovery of renal function in patients with lupus nephritis and reduced renal function: the beneficial effect of hydroxychloroquine. Lupus, 2020, 29, 52-57.	0.8	18
39	Negative Regulation of Osteoclast Commitment by Intracellular Protein Phosphatase Magnesiumâ€Dependent 1A. Arthritis and Rheumatology, 2020, 72, 750-760.	2.9	12
40	Clinical and histological significance of urinary CD11c+ macrophages in lupus nephritis. Arthritis Research and Therapy, 2020, 22, 173.	1.6	8
41	Effect of Vitamin D Supplementation on Bone Mineral Density in Rheumatoid Arthritis Patients With Osteoporosis. Frontiers in Medicine, 2020, 7, 443.	1.2	6
42	Sixâ€month flare risk after discontinuing longâ€term methotrexate treatment in patients having rheumatoid arthritis with low disease activity. International Journal of Rheumatic Diseases, 2020, 23, 1076-1081.	0.9	2
43	Autoantibodies against Protein Phosphatase Magnesium-Dependent 1A as a Biomarker for Predicting Radiographic Progression in Ankylosing Spondylitis Treated with Anti-Tumor Necrosis Factor Agents. Journal of Clinical Medicine, 2020, 9, 3968.	1.0	4
44	Prognostic factors for steroid-free remission in patients with idiopathic inflammatory myopathies: importance of anthropometric measurements. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2093682.	1.2	2
45	Early discontinuation of tofacitinib in patients with rheumatoid arthritis co-treated with rifampin for latent tuberculosis. Joint Bone Spine, 2020, 87, 475-479.	0.8	8
46	Methotrexate-related toxicity in patients with rheumatoid arthritis and renal dysfunction. Rheumatology International, 2020, 40, 765-770.	1.5	24
47	Immunological characteristics and possible pathogenic role of urinary CD11c+ macrophages in lupus nephritis. Rheumatology, 2020, 59, 2135-2145.	0.9	24
48	Plasma immunoglobulin binding protein 1 as a predictor of development of lupus nephritis. Lupus, 2020, 29, 547-553.	0.8	6
49	An updated review of infliximab biosimilar, CT-P13, in the treatment of immune-mediated inflammatory diseases. Immunotherapy, 2020, 12, 609-623.	1.0	3
50	Highâ€Throughput Algorithm for Discovering New Drug Indications by Utilizing Largeâ€Scale Electronic Medical Record Data. Clinical Pharmacology and Therapeutics, 2020, 108, 1299-1307.	2.3	7
51	Rapid reduction in uric acid by a urate-lowering agent is associated with recurrent cardiovascular events. Medical Hypotheses, 2020, 141, 109740.	0.8	9
52	Seroconversion to antinuclear antibody negativity and its association with disease flare in patients with systemic lupus erythematosus. Lupus, 2020, 29, 697-704.	0.8	8
53	Effects of dihydrotestosterone on osteoblast activity in curdlan-administered SKG mice and osteoprogenitor cells in patients with ankylosing spondylitis. Arthritis Research and Therapy, 2020, 22, 121.	1.6	8
54	Efficacy and Safety of Rituximab in Korean Patients with Refractory Inflammatory Myopathies. Journal of Korean Medical Science, 2020, 35, e335.	1.1	4

#	Article	IF	CITATIONS
55	Clinical features and recurrent attack in gout patients according to serum urate levels during an acute attack. Korean Journal of Internal Medicine, 2020, 35, 240-248.	0.7	19
56	Comparison of Clinical, Angiographic Features and Outcome in Takayasu's Arteritis and Behçet's Disease With Arterial Involvement. Journal of Rheumatic Diseases, 2020, 27, 100.	0.4	4
57	Liver enzyme elevation in patients with ankylosing spondylitis treated with tumor necrosis factor inhibitors: a single-center historical cohort study. Korean Journal of Internal Medicine, 2020, 35, 723-731.	0.7	6
58	Factors associated with aggravation of tubulointerstitial damage on repeated biopsies in lupus nephritis patients with treatment failure. Clinical and Experimental Rheumatology, 2020, 38, 239-244.	0.4	0
59	Non-albumin proteinuria as a parameter of tubulointerstitial inflammation in lupus nephritis. Clinical Rheumatology, 2019, 38, 235-241.	1.0	9
60	Clinical features and prognoses of acute transverse myelitis in patients with systemic lupus erythematosus. Korean Journal of Internal Medicine, 2019, 34, 442-451.	0.7	11
61	Clinical significance of autoantibody positivity in idiopathic pulmonary fibrosis. Respiratory Medicine, 2019, 155, 43-48.	1.3	14
62	Renal flare in class V lupus nephritis: increased risk in patients with tubulointerstitial lesions. Rheumatology International, 2019, 39, 2061-2067.	1.5	7
63	Serum uric acid level and subclinical coronary atherosclerosis in asymptomatic individuals: An observational cohort study. Atherosclerosis, 2019, 288, 112-117.	0.4	16
64	Tocilizumab-induced Thrombocytopenia in Patients with Rheumatoid Arthritis. Journal of Rheumatic Diseases, 2019, 26, 186.	0.4	8
65	Effects of Pregnancy and Delivery Methods on Change in Ankylosing Spondylitis Treatment Using the Korean Health Insurance Review and Assessment Service Claims Database. Journal of Korean Medical Science, 2019, 34, e238.	1.1	3
66	Impact of stringent response in proteinuria on long-term renal outcomes in proliferative lupus nephritis. Lupus, 2019, 28, 1294-1301.	0.8	6
67	Fate of Abstracts Presented at the Korean College of Rheumatology Annual Scientific Meetings. Journal of Rheumatic Diseases, 2019, 26, 41.	0.4	1
68	Immunoglobulin Binding Protein 1 as a Potential Urine Biomarker in Patients with Lupus Nephritis. International Journal of Molecular Sciences, 2019, 20, 2606.	1.8	12
69	Reply to: Challenging therapeutic goal in large vessel vasculitis. International Journal of Cardiology, 2019, 287, 127.	0.8	0
70	Prefoldin 5 and Anti-prefoldin 5 Antibodies as Biomarkers for Uveitis in Ankylosing Spondylitis. Frontiers in Immunology, 2019, 10, 384.	2.2	14
71	Statins reduce relapse rate in Takayasu arteritis. International Journal of Cardiology, 2019, 287, 111-115.	0.8	21
72	Interleukinâ€32γ: Possible association with the activity and development of nephritis in patients with systemic lupus erythematosus. International Journal of Rheumatic Diseases, 2019, 22, 1305-1311.	0.9	6

#	Article	IF	CITATIONS
73	AB0174â€CLINICAL SIGNIFICANCE OF THE URINARY CD11C+ MYELOID CELLS IN THE PATIENTS WITH LUPUS NEPHRITIS. , 2019, , .		0
74	FRI0243â€RECOVERY OF RENAL FUNCTION IN PATIENTS WITH LUPUS NEPHRITIS AND REDUCED RENAL FUNCTION. , 2019, , .		0
75	AB0724â€DOSE PREGNANCY AND VAGINAL DELIVERY WORSEN ANKYLOSING SPONDYLITIS?. , 2019, , .		0
76	Effect of tumor necrosis factor inhibition on spinal inflammation and spinal ankylosis in SKG mice. Scientific Reports, 2019, 9, 18000.	1.6	7
77	Hepatic Safety of Febuxostat Compared with Allopurinol in Gout Patients with Fatty Liver Disease. Journal of Rheumatology, 2019, 46, 527-531.	1.0	9
78	Prominent Inflammatory Features of Monocytes/Macrophages in Acute Calcium Pyrophosphate Crystal Arthritis: a Comparison with Acute Gouty Arthritis. Immune Network, 2019, 19, e21.	1.6	9
79	Clinical features and risk of recurrence of acute calcium pyrophosphate crystal arthritis. Clinical and Experimental Rheumatology, 2019, 37, 254-259.	0.4	3
80	Conventional synthetic disease-modifying antirheumatic drugs and bone mineral density in rheumatoid arthritis patients with osteoporosis: possible beneficial effect of leflunomide. Clinical and Experimental Rheumatology, 2019, 37, 813-819.	0.4	8
81	Predicting eventual development of lupus nephritis at the time of diagnosis of systemic lupus erythematosus. Seminars in Arthritis and Rheumatism, 2018, 48, 462-466.	1.6	30
82	Safety of the concomitant use of methotrexate and a prophylactic dose of trimethoprim-sulfamethoxazole. Clinical Rheumatology, 2018, 37, 3215-3220.	1.0	17
83	The risk of herpes zoster in patients with ankylosing spondylitis: Analysis of the Korean National Health Insurance Service – Sample cohort database. Modern Rheumatology, 2018, 28, 168-173.	0.9	17
84	SAT0602â€Clinical significance of autoantibody positivity in idiopathic pulmonary fibrosis. , 2018, , .		0
85	AB0705â€Long-term outcomes and prognostic factors associated with aortic valve surgery in patients with takayasu arteritis and aortic valveregurgitation. , 2018, , .		0
86	The usefulness of routine chest radiograph examinations in patients treated with TNF inhibitors for inflammatory arthritis in South Korea. Respiratory Medicine, 2018, 143, 109-115.	1.3	4
87	Role of IL-32 Gamma on Bone Metabolism in Autoimmune Arthritis. Immune Network, 2018, 18, e20.	1.6	11
88	In-stent Restenosis after Drug-eluting Stent Implantation in Rheumatoid Arthritis: Possible Protective Effect of Methotrexate. Journal of Rheumatology, 2018, 45, 1336-1338.	1.0	1
89	IL-17A+GM-CSF+ Neutrophils Are the Major Infiltrating Cells in Interstitial Lung Disease in an Autoimmune Arthritis Model. Frontiers in Immunology, 2018, 9, 1544.	2.2	18
90	Extravascular manifestations of Takayasu arteritis: focusing on the features shared with spondyloarthritis. Arthritis Research and Therapy, 2018, 20, 142.	1.6	20

#	Article	IF	CITATIONS
91	Comparison of latent tuberculosis infection screening strategies before tumor necrosis factor inhibitor treatment in inflammatory arthritis: IGRA-alone versus combination of TST and IGRA. PLoS ONE, 2018, 13, e0198756.	1.1	9
92	Reduction or cessation of antiviral agents in hepatitis B virus carriers treated with biologic agents. Clinical and Experimental Rheumatology, 2018, 36, 170.	0.4	0
93	Interleukin-32 Gamma Stimulates Bone Formation by Increasing miR-29a in Osteoblastic Cells and Prevents the Development of Osteoporosis. Scientific Reports, 2017, 7, 40240.	1.6	23
94	Risk of Colchicine-Associated Myopathy in Gout: Influence of Concomitant Use of Statin. American Journal of Medicine, 2017, 130, 583-587.	0.6	23
95	Longterm Outcomes of Renal Artery Involvement in Takayasu Arteritis. Journal of Rheumatology, 2017, 44, 466-472.	1.0	18
96	The Reply. American Journal of Medicine, 2017, 130, e469.	0.6	0
97	Neutrophil-to-lymphocyte ratio is a reliable marker of treatment response in rheumatoid arthritis patients during tocilizumab therapy. Modern Rheumatology, 2017, 27, 405-410.	0.9	23
98	FRIO316â€Factors associated with surgical outcomes of severe aortic regurgitation in patients with behcet's disease. , 2017, , .		0
99	FRI0181â€Tapering or cessation of antiviral agent in hepatitis b virus-infected patients concomitantly treated with biologic agents. , 2017, , .		0
100	AB0491â€The association of baseline hyperuricemia in premenopausal women with systemic lupus erythematosus and development of nephritis. , 2017, , .		0
101	lleocolonoscopic findings in patients with ankylosing spondylitis: a single center retrospective study. Korean Journal of Internal Medicine, 2017, 32, 916-922.	0.7	5
102	Calcific Uremic Arteriolopathy Revealed Via Hand Radiography. Journal of Rheumatic Diseases, 2017, 25, 148.	0.4	0
103	CD14+ Cells with the Phenotype of Infiltrated Monocytes Consist of Distinct Populations Characterized by Anti-inflammatory as well as Pro-inflammatory Activity in Gouty Arthritis. Frontiers in Immunology, 2017, 8, 1260.	2.2	24
104	Nontuberculous mycobacterial infection in rheumatoid arthritis patients: a single-center experience in South Korea. Korean Journal of Internal Medicine, 2017, 32, 1090-1097.	0.7	9
105	Association between Treatment with Biologic Agents and the Incidence of Herpes Zoster in Rheumatoid Arthritis. Journal of Rheumatic Diseases, 2017, 24, 251.	0.4	0
106	THU0381â€The Incidence of Herpes Zoster Infection in Patients with Ankylosing Spondylitis: Analysis from Korean National Health Insurance Service–Cohort Sample Database: Table 1 Annals of the Rheumatic Diseases, 2016, 75, 325.2-326.	0.5	0
107	A Case of Infliximab-induced Multifocal Motor Neuropathy in a Patient with Rheumatoid Arthritis and Literature Review. Journal of Rheumatic Diseases, 2016, 23, 250.	0.4	2
108	Immunoglobulin G Levels as a Prognostic Factor for Autoimmune Hepatitis Combined With Systemic Lupus Erythematosus. Arthritis Care and Research, 2016, 68, 995-1002.	1.5	14

#	Article	IF	CITATIONS
109	FRIO401â€Safety of Resuming Tumor Necrosis Factor Inhibitors in Ankylosing Spondylitis Patients Concomitant with The Treatment of Active Tuberculosis: A Retrospective Nationwide Registry of The Korean Society of Spondyloarthritis Research. Annals of the Rheumatic Diseases, 2016, 75, 580.2-581.	0.5	0
110	AB0804â€The Efficacy and Tolerability of Febuxostat in Hyperuricemic Patients Undergoing Dialysis. Annals of the Rheumatic Diseases, 2016, 75, 1178.3-1179.	0.5	0
111	Febuxostat in Hyperuricemic Patients With Advanced CKD. American Journal of Kidney Diseases, 2016, 68, 819-821.	2.1	14
112	Clinical outcomes of hydronephrosis in patients with systemic lupus erythematosus. International Journal of Rheumatic Diseases, 2016, 19, 1317-1321.	0.9	10
113	FRI0124â€Nontuberculous Mycobacterial Infection in Rheumatoid Arthritis Patients: A Single-Center Experience in South Korea: Table 1 Annals of the Rheumatic Diseases, 2016, 75, 473.1-473.	0.5	0
114	Safety of tumor necrosis factor inhibitor therapy in patients with a prior malignancy. International Journal of Rheumatic Diseases, 2016, 19, 961-967.	0.9	2
115	Adequacy of initiating TNF antagonists within 3 weeks of starting latent tuberculosis infection treatment in patients with immune-mediated inflammatory diseases. Infectious Diseases, 2016, 48, 293-298.	1.4	3
116	Interleukin-33 acts as a transcriptional repressor and extracellular cytokine in fibroblast-like synoviocytes in patients with rheumatoid arthritis. Cytokine, 2016, 77, 35-43.	1.4	37
117	Safety of Resuming Tumor Necrosis Factor Inhibitors in Ankylosing Spondylitis Patients Concomitant with the Treatment of Active Tuberculosis: A Retrospective Nationwide Registry of the Korean Society of Spondyloarthritis Research. PLoS ONE, 2016, 11, e0153816.	1.1	15
118	Endoscopic Findings of Upper Gastrointestinal Involvement in Primary Vasculitis. Gut and Liver, 2016, 10, 542-548.	1.4	24
119	Late-onset IgA vasculitis in adult patients exhibits distinct clinical characteristics and outcomes. Clinical and Experimental Rheumatology, 2016, 34, S77-83.	0.4	13
120	AB0612â€Clinical Outcomes of Hydronephrosis in Patients with Systemic Lupus Erythematosus. Annals of the Rheumatic Diseases, 2015, 74, 1104.2-1104.	0.5	0
121	AB0613â€Predictive Role of Low Vitamin D Levels in Lupus Nephritis Flare. Annals of the Rheumatic Diseases, 2015, 74, 1104.3-1104.	0.5	0
122	High level of interleukin-32 gamma in the joint of ankylosing spondylitis is associated with osteoblast differentiation. Arthritis Research and Therapy, 2015, 17, 350.	1.6	25
123	FRI0427â€Clinical Outcomes of Acute Transverse Myelitis in Patients with Systemic Lupus Erythematosus. Annals of the Rheumatic Diseases, 2015, 74, 581.3-581.	0.5	0
124	The Incidence of Uveitis in Ankylosing Spondylitis Patients Undergoing Tumor Necrosis Factor Inhibiting Therapy in Korea. Journal of Rheumatic Diseases, 2015, 22, 288.	0.4	3
125	An Atraumatic Fracture of the Odontoid Process in a Newly Diagnosed Rheumatoid Arthritis Patient. Journal of Rheumatic Diseases, 2015, 22, 102.	0.4	1
126	Factors related to outcomes in lupus-related protein-losing enteropathy. Korean Journal of Internal Medicine, 2015, 30, 906-912.	0.7	7

#	Article	lF	CITATIONS
127	Comparison of LTBI treatment regimens for patients receiving anti-tumour necrosis factor therapy. International Journal of Tuberculosis and Lung Disease, 2015, 19, 342-348.	0.6	22
128	TNF-α confers resistance to Fas-mediated apoptosis in rheumatoid arthritis through the induction of soluble Fas. Life Sciences, 2015, 122, 37-41.	2.0	10
129	Lupus enteritis: clinical characteristics and predictive factors for recurrence. Lupus, 2015, 24, 628-632.	0.8	33
130	Outcome of Takayasu Arteritis with Inactive Disease at Diagnosis: The Extent of Vascular Involvement As a Predictor of Activation. Journal of Rheumatology, 2015, 42, 489-494.	1.0	12
131	Mortality in patients with rheumatoid arthritis-associated interstitial lung disease treated with an anti-tumor necrosis factor agent. Korean Journal of Internal Medicine, 2015, 30, 104.	0.7	30
132	Non-Infective Endocarditis in a Patient with Rheumatoid Arthritis. Korean Journal of Medicine, 2015, 88, 110.	0.1	0
133	SAT0013â€Lupus Enteritis: Clinical Characteristics and Risk Factors Associated with Recurrence. Annals of the Rheumatic Diseases, 2014, 73, 594.1-594.	0.5	Ο
134	Role of Protein Phosphatase Magnesiumâ€Dependent 1A and Anti–Protein Phosphatase Magnesiumâ€Dependent 1A Autoantibodies in Ankylosing Spondylitis. Arthritis and Rheumatology, 2014, 66, 2793-2803.	2.9	29
135	Safety of resuming tumour necrosis factor inhibitors in patients who developed tuberculosis as a complication of previous TNF inhibitors. Rheumatology, 2014, 53, 1477-1481.	0.9	28
136	Diagnosis of latent tuberculosis infection before initiation of anti-tumor necrosis factor therapy using both tuberculin skin test and QuantiFERON-TB Gold In Tube assay. Scandinavian Journal of Infectious Diseases, 2014, 46, 763-769.	1.5	25
137	Mycobacterial diseases developed during anti-tumour necrosis factor-α therapy. European Respiratory Journal, 2014, 44, 1289-1295.	3.1	46
138	SAT0522â€The Association between Uric Acid Level and Urolithiasis on Ultrasonography. Annals of the Rheumatic Diseases, 2014, 73, 780.2-780.	0.5	3
139	THU0067â€The Incidence of New Onset and Recurrent Uveitis in Ankylosing Spondylitis Patients during TNF Inhibitor Therapy in Korean. Annals of the Rheumatic Diseases, 2014, 73, 200.1-200.	0.5	0
140	AB0154â€Pathogenic Role of Irhom2 in Seropositive Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2014, 73, 854.2-854.	0.5	0
141	AB0500â€B-Cell Depleting Therapy for SLE Related Refractory Thrombocytopenia. Annals of the Rheumatic Diseases, 2014, 73, 972.2-972.	0.5	0
142	The â€~either test positive' strategy for latent tuberculous infection before anti-tumour necrosis factor treatment. International Journal of Tuberculosis and Lung Disease, 2014, 18, 428-434.	0.6	22
143	Assessment of Peripheral Neuropathy in Patients With Rheumatoid Arthritis Who Complain of Neurologic Symptoms. Annals of Rehabilitation Medicine, 2014, 38, 249.	0.6	36
144	Protective effects of ginsenoside Rg3 on human osteoarthritic chondrocytes. Modern Rheumatology, 2013, 23, 104-111.	0.9	24

#	Article	IF	CITATIONS
145	THU0267â€A randomized controlled trial of the efficacy of incentive spirometer exercise on pulmonary functions of patients with ankylosing spondylitis stabilized by tumor necrosis factor inhibitor therapy. Annals of the Rheumatic Diseases, 2013, 71, 245.1-245.	0.5	0
146	SAT0097â€Changes In Bone Mineral Density in Patients with Recent-Onset Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2013, 72, A612.2-A612.	0.5	0
147	AB0484â€Analysis of factors predictive of survival based on 24 patients with systemic granulomatosis with polyangiitis in korea. Annals of the Rheumatic Diseases, 2013, 72, A936.4-A937.	0.5	0
148	SAT0330â€Sclerostin concentrations in plasma and synovial fluid inversely correlate with disease severity in knee osteoarthritis. Annals of the Rheumatic Diseases, 2013, 71, 583.3-584.	0.5	0
149	FRIO210â€Mortality in patients with rheumatoid arthritis-associated interstitial lung disease treated with an anti-tumor necrosis factor agent. Annals of the Rheumatic Diseases, 2013, 72, A444.1-A444.	0.5	0
150	SAT0123â€Reactivation of latent tuberculosis infection and new infection of tuberculosis in patients with anti-tumor necrosis factor therapy for tuberculosis-endemic area. Annals of the Rheumatic Diseases, 2013, 71, 512.1-512.	0.5	0
151	A Case of Adult-Onset Still's Disease Presenting with Periorbital Edema. Journal of Rheumatic Diseases, 2013, 20, 243.	0.4	0
152	AB0337â€Blood b cell counts as predictor of early clinical response after rituximab in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 72, A890.3-A890.	0.5	0
153	Elevated interleukin-32 expression in granulomatosis with polyangiitis. Rheumatology, 2012, 51, 1979-1988.	0.9	19
154	Combined use of a TST and the T-SPOT®. <i>TB</i> assay for latent tuberculosis infection diagnosis before anti-TNF-α treatment. International Journal of Tuberculosis and Lung Disease, 2012, 16, 1300-1306.	0.6	27
155	The Influence of Interleukin-32γ on Osteoclastogenesis with a Focus on Fusion-Related Genes. Journal of Clinical Immunology, 2012, 32, 201-206.	2.0	7
156	A Case of Adult-onset Still's Disease in a Patient with Ankylosing Spondylitis Complicated with Crohn's Disease. Journal of Rheumatic Diseases, 2011, 18, 142.	0.4	1
157	Interleukin-33 stimulates formation of functional osteoclasts from human CD14+ monocytes. Cellular and Molecular Life Sciences, 2010, 67, 3883-3892.	2.4	83
158	Interleukin-32Î ³ Enhances the Production of IL-6 and IL-8 in Fibroblast-Like Synoviocytes Via Erk1/2 Activation. Journal of Clinical Immunology, 2010, 30, 260-267.	2.0	15
159	Effect of interleukinâ€32γ on differentiation of osteoclasts from CD14+ monocytes. Arthritis and Rheumatism, 2010, 62, 515-523.	6.7	43
160	Successful rituximab treatment of refractory hemophagocytic lymphohistiocytosis and autoimmune hemolytic anemia associated with systemic lupus erythematosus. Modern Rheumatology, 0, , 1.	0.9	3
161	Circulating and renal fibrocytes are associated with interstitial fibrosis in lupus nephritis. Rheumatology, 0, , .	0.9	1